Hepatitis B – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Hepatitis B – Pipeline Review, H2 2016’, provides an overview of the Hepatitis B pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hepatitis B, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hepatitis B and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Hepatitis B

The report reviews pipeline therapeutics for Hepatitis B by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Hepatitis B therapeutics and enlists all their major and minor projects

The report assesses Hepatitis B therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Hepatitis B

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Hepatitis B

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Hepatitis B pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Abivax SA

AiCuris GmbH & Co KG

AIMM Therapeutics BV

Akshaya Bio Inc

Alnylam Pharmaceuticals Inc

AlphaMab Co., Ltd

Altimmune Inc

Altravax Inc

Amarna Therapeutics BV

Arbutus Biopharma Corp

Arcturus Therapeutics Inc

Arrowhead Pharmaceuticals Inc

Assembly Biosciences Inc

Beijing Kawin Technology Share-Holding Co Ltd

Beijing Minhai Biotechnology Co Ltd

Benitec Biopharma Ltd

Biogenomics Limited

Biological E Ltd

BioStar Pharmaceuticals Inc

Bolder Biotechnology Inc

BrightGene Bio-Medical Technology Co Ltd

Bukwang PharmCo Ltd

CaroGen Corp

Celltrion Inc

Chong Kun Dang Pharmaceutical Corp

Chromis Therapeutics, Inc.

ChronTech Pharma AB

Cocrystal Pharma Inc

ContraVir Pharmaceuticals Inc

CyTuVax BV

Dicerna Pharmaceuticals Inc

Dong-A Socio Holdings Co Ltd

Dynavax Technologies Corp

Ensemble Therapeutics Corp

eTheRNA Immunotherapies NV

F. Hoffmann-La Roche Ltd

GeneCure LLC

GeoVax Labs Inc

Gilead Sciences Inc

GlaxoSmithKline Plc

Green Cross Corp

Hanmi Pharmaceuticals Co Ltd

HEC Pharm Co., Ltd.

Humabs BioMed SA

Huons Co Ltd

Ildong Pharmaceutical Co Ltd

Immunotope Inc

Indian Immunologicals Ltd

Intellia Therapeutics Inc

Ionis Pharmaceuticals Inc

ISA Pharmaceuticals BV

Jiangsu Hansoh Pharmaceutical Co Ltd

Johnson & Johnson

Kineta Inc

Lakewood-Amedex Inc

Leukocare AG

LG Life Science LTD

Ligand Pharmaceuticals Inc

Mucosis BV

MultiCell Technologies Inc

Oncolys BioPharma Inc

Panacea Biotec Ltd

Pfenex Inc

PharmaEssentia Corp

Poxel SA

Profarma

Profectus BioSciences Inc

Redx Pharma Plc

REPLICor Inc

Rodos BioTarget GmbH

Samjin Pharmaceutical Co Ltd

Sanofi Pasteur SA

Shantha Biotechnics Ltd

Sinovac Biotech Ltd

Spring Bank Pharmaceuticals Inc

Staidson (Beijing) Biopharmaceuticals Co., Ltd.

TCM Biotech International Corp

TetraLogic Pharmaceuticals

TGV-Laboratories

Theravectys SA

Tomegavax Inc

Transgene SA

Vaxine Pty Ltd

VBI Vaccines Inc

Viriom Ltd

VLP Biotech Inc

Zydus Cadila Healthcare Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 7

Hepatitis B Overview 8

Therapeutics Development 9

Hepatitis B - Therapeutics under Development by Companies 11

Hepatitis B - Therapeutics under Investigation by Universities/Institutes 19

Hepatitis B - Pipeline Products Glance 20

Hepatitis B - Products under Development by Companies 24

Hepatitis B - Products under Investigation by Universities/Institutes 33

Hepatitis B - Companies Involved in Therapeutics Development 34

Hepatitis B - Therapeutics Assessment 121

Drug Profiles 133

Hepatitis B - Dormant Projects 345

Hepatitis B - Discontinued Products 357

Hepatitis B - Product Development Milestones 358

Appendix 369

List of Tables

List of Tables

Number of Products under Development for Hepatitis B, H2 2016 27

Number of Products under Development for Hepatitis B – Comparative Analysis, H2 2016 28

Number of Products under Development by Companies, H2 2016 30

Number of Products under Development by Companies, H2 2016 (Contd..1) 31

Number of Products under Development by Companies, H2 2016 (Contd..2) 32

Number of Products under Development by Companies, H2 2016 (Contd..3) 33

Number of Products under Development by Companies, H2 2016 (Contd..4) 34

Number of Products under Development by Companies, H2 2016 (Contd..5) 35

Number of Products under Development by Companies, H2 2016 (Contd..6) 36

Number of Products under Investigation by Universities/Institutes, H2 2016 37

Comparative Analysis by Late Stage Development, H2 2016 38

Comparative Analysis by Clinical Stage Development, H2 2016 39

Comparative Analysis by Early Stage Development, H2 2016 40

Comparative Analysis by Unknown Stage Development, H2 2016 41

Products under Development by Companies, H2 2016 42

Products under Development by Companies, H2 2016 (Contd..1) 43

Products under Development by Companies, H2 2016 (Contd..2) 44

Products under Development by Companies, H2 2016 (Contd..3) 45

Products under Development by Companies, H2 2016 (Contd..4) 46

Products under Development by Companies, H2 2016 (Contd..5) 47

Products under Development by Companies, H2 2016 (Contd..6) 48

Products under Development by Companies, H2 2016 (Contd..7) 49

Products under Development by Companies, H2 2016 (Contd..8) 50

Products under Investigation by Universities/Institutes, H2 2016 51

Hepatitis B – Pipeline by Abivax SA, H2 2016 52

Hepatitis B – Pipeline by AiCuris GmbH & Co KG, H2 2016 53

Hepatitis B – Pipeline by AIMM Therapeutics BV, H2 2016 54

Hepatitis B – Pipeline by Akshaya Bio Inc, H2 2016 55

Hepatitis B – Pipeline by Alnylam Pharmaceuticals Inc, H2 2016 56

Hepatitis B – Pipeline by AlphaMab Co., Ltd, H2 2016 57

Hepatitis B – Pipeline by Altimmune Inc, H2 2016 58

Hepatitis B – Pipeline by Altravax Inc, H2 2016 59

Hepatitis B – Pipeline by Amarna Therapeutics BV, H2 2016 60

Hepatitis B – Pipeline by Arbutus Biopharma Corp, H2 2016 61

Hepatitis B – Pipeline by Arcturus Therapeutics Inc, H2 2016 62

Hepatitis B – Pipeline by Arrowhead Pharmaceuticals Inc, H2 2016 63

Hepatitis B – Pipeline by Assembly Biosciences Inc, H2 2016 64

Hepatitis B – Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, H2 2016 65

Hepatitis B – Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2016 66

Hepatitis B – Pipeline by Benitec Biopharma Ltd, H2 2016 67

Hepatitis B – Pipeline by Biogenomics Limited, H2 2016 68

Hepatitis B – Pipeline by Biological E Ltd, H2 2016 69

Hepatitis B – Pipeline by BioStar Pharmaceuticals Inc, H2 2016 70

Hepatitis B – Pipeline by Bolder Biotechnology Inc, H2 2016 71

Hepatitis B – Pipeline by BrightGene Bio-Medical Technology Co Ltd, H2 2016 72

Hepatitis B – Pipeline by Bukwang PharmCo Ltd, H2 2016 73

Hepatitis B – Pipeline by CaroGen Corp, H2 2016 74

Hepatitis B – Pipeline by Celltrion Inc, H2 2016 75

Hepatitis B – Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2016 76

Hepatitis B – Pipeline by Chromis Therapeutics, Inc., H2 2016 77

Hepatitis B – Pipeline by ChronTech Pharma AB, H2 2016 78

Hepatitis B – Pipeline by Cocrystal Pharma Inc, H2 2016 79

Hepatitis B – Pipeline by ContraVir Pharmaceuticals Inc, H2 2016 80

Hepatitis B – Pipeline by CyTuVax BV, H2 2016 81

Hepatitis B – Pipeline by Dicerna Pharmaceuticals Inc, H2 2016 82

Hepatitis B – Pipeline by Dong-A Socio Holdings Co Ltd, H2 2016 83

Hepatitis B – Pipeline by Dynavax Technologies Corp, H2 2016 84

Hepatitis B – Pipeline by Ensemble Therapeutics Corp, H2 2016 85

Hepatitis B – Pipeline by eTheRNA Immunotherapies NV, H2 2016 86

Hepatitis B – Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 87

Hepatitis B – Pipeline by GeneCure LLC, H2 2016 88

Hepatitis B – Pipeline by GeoVax Labs Inc, H2 2016 89

Hepatitis B – Pipeline by Gilead Sciences Inc, H2 2016 90

Hepatitis B – Pipeline by GlaxoSmithKline Plc, H2 2016 91

Hepatitis B – Pipeline by Green Cross Corp, H2 2016 92

Hepatitis B – Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2016 93

Hepatitis B – Pipeline by HEC Pharm Co., Ltd., H2 2016 94

Hepatitis B – Pipeline by Humabs BioMed SA, H2 2016 95

Hepatitis B – Pipeline by Huons Co Ltd, H2 2016 96

Hepatitis B – Pipeline by Ildong Pharmaceutical Co Ltd, H2 2016 97

Hepatitis B – Pipeline by Immunotope Inc, H2 2016 98

Hepatitis B – Pipeline by Indian Immunologicals Ltd, H2 2016 99

Hepatitis B – Pipeline by Intellia Therapeutics Inc, H2 2016 100

Hepatitis B – Pipeline by Ionis Pharmaceuticals Inc, H2 2016 101

Hepatitis B – Pipeline by ISA Pharmaceuticals BV, H2 2016 102

Hepatitis B – Pipeline by Jiangsu Hansoh Pharmaceutical Co Ltd, H2 2016 103

Hepatitis B – Pipeline by Johnson & Johnson, H2 2016 104

Hepatitis B – Pipeline by Kineta Inc, H2 2016 105

Hepatitis B – Pipeline by Lakewood-Amedex Inc, H2 2016 106

Hepatitis B – Pipeline by Leukocare AG, H2 2016 107

Hepatitis B – Pipeline by LG Life Science LTD, H2 2016 108

Hepatitis B – Pipeline by Ligand Pharmaceuticals Inc, H2 2016 109

Hepatitis B – Pipeline by Mucosis BV, H2 2016 110

Hepatitis B – Pipeline by MultiCell Technologies Inc, H2 2016 111

Hepatitis B – Pipeline by Oncolys BioPharma Inc, H2 2016 112

Hepatitis B – Pipeline by Panacea Biotec Ltd, H2 2016 113

Hepatitis B – Pipeline by Pfenex Inc, H2 2016 114

Hepatitis B – Pipeline by PharmaEssentia Corp, H2 2016 115

Hepatitis B – Pipeline by Poxel SA, H2 2016 116

Hepatitis B – Pipeline by Profarma, H2 2016 117

Hepatitis B – Pipeline by Profectus BioSciences Inc, H2 2016 118

Hepatitis B – Pipeline by Redx Pharma Plc, H2 2016 119

Hepatitis B – Pipeline by REPLICor Inc, H2 2016 120

Hepatitis B – Pipeline by Rodos BioTarget GmbH, H2 2016 121

Hepatitis B – Pipeline by Samjin Pharmaceutical Co Ltd, H2 2016 122

Hepatitis B – Pipeline by Sanofi Pasteur SA, H2 2016 123

Hepatitis B – Pipeline by Shantha Biotechnics Ltd, H2 2016 124

Hepatitis B – Pipeline by Sinovac Biotech Ltd, H2 2016 125

Hepatitis B – Pipeline by Spring Bank Pharmaceuticals Inc, H2 2016 126

Hepatitis B – Pipeline by Staidson (Beijing) Biopharmaceuticals Co., Ltd., H2 2016 127

Hepatitis B – Pipeline by TCM Biotech International Corp, H2 2016 128

Hepatitis B – Pipeline by TetraLogic Pharmaceuticals, H2 2016 129

Hepatitis B – Pipeline by TGV-Laboratories, H2 2016 130

Hepatitis B – Pipeline by Theravectys SA, H2 2016 131

Hepatitis B – Pipeline by Tomegavax Inc, H2 2016 132

Hepatitis B – Pipeline by Transgene SA, H2 2016 133

Hepatitis B – Pipeline by Vaxine Pty Ltd, H2 2016 134

Hepatitis B – Pipeline by VBI Vaccines Inc, H2 2016 135

Hepatitis B – Pipeline by Viriom Ltd, H2 2016 136

Hepatitis B – Pipeline by VLP Biotech Inc, H2 2016 137

Hepatitis B – Pipeline by Zydus Cadila Healthcare Ltd, H2 2016 138

Assessment by Monotherapy Products, H2 2016 139

Assessment by Combination Products, H2 2016 140

Number of Products by Stage and Target, H2 2016 142

Number of Products by Stage and Mechanism of Action, H2 2016 145

Number of Products by Stage and Route of Administration, H2 2016 148

Number of Products by Stage and Molecule Type, H2 2016 150

Hepatitis B – Dormant Projects, H2 2016 363

Hepatitis B – Dormant Projects (Contd..1), H2 2016 364

Hepatitis B – Dormant Projects (Contd..2), H2 2016 365

Hepatitis B – Dormant Projects (Contd..3), H2 2016 366

Hepatitis B – Dormant Projects (Contd..4), H2 2016 367

Hepatitis B – Dormant Projects (Contd..5), H2 2016 368

Hepatitis B – Dormant Projects (Contd..6), H2 2016 369

Hepatitis B – Dormant Projects (Contd..7), H2 2016 370

Hepatitis B – Dormant Projects (Contd..8), H2 2016 371

Hepatitis B – Dormant Projects (Contd..9), H2 2016 372

Hepatitis B – Dormant Projects (Contd..10), H2 2016 373

Hepatitis B – Dormant Projects (Contd..11), H2 2016 374

Hepatitis B – Discontinued Products, H2 2016 375

List of Figures

List of Figures

Number of Products under Development for Hepatitis B, H2 2016 27

Number of Products under Development for Hepatitis B – Comparative Analysis, H2 2016 28

Number of Products under Development by Companies, H2 2016 29

Number of Products under Investigation by Universities/Institutes, H2 2016 37

Comparative Analysis by Late Stage Development, H2 2016 38

Comparative Analysis by Clinical Stage Development, H2 2016 39

Comparative Analysis by Early Stage Products, H2 2016 40

Assessment by Monotherapy Products, H2 2016 139

Assessment by Combination Products, H2 2016 140

Number of Products by Top 10 Targets, H2 2016 141

Number of Products by Stage and Top 10 Targets, H2 2016 141

Number of Products by Top 10 Mechanism of Actions, H2 2016 144

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 144

Number of Products by Routes of Administration, H2 2016 147

Number of Products by Stage and Routes of Administration, H2 2016 147

Number of Products by Top 10 Molecule Types, H2 2016 149

Number of Products by Stage and Top 10 Molecule Types, H2 2016 149

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports